Literature DB >> 16046904

Administration-time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure.

Ramón C Hermida1, Diana E Ayala, Carlos Calvo.   

Abstract

PURPOSE OF REVIEW: Many studies show that the extent of the nocturnal blood-pressure decline is deterministic of cardiovascular injury and risk. Accordingly, there is growing interest in how to tailor the treatment of hypertensive patients according to their circadian blood-pressure pattern. RECENT
FINDINGS: Differences in efficacy depending on the time of day of drug administration lead to differences in effects of antihypertensive drugs on the nocturnal decline relative to the diurnal mean of blood pressure. Thus, bedtime dosing with nifedipine gastrointestinal therapeutic system (GITS) is more effective than morning dosing, while also reducing significantly secondary effects. Bedtime administration of trandolapril results in a safe and effective means of controlling morning blood pressure without inducing excessive reduction nocturnally. The dose-response curve, therapeutic coverage, and efficacy of doxazosin GITS are all markedly dependent on the circadian time of drug administration. Moreover, valsartan administration at bedtime as opposed to upon wakening results in improved day/night blood-pressure ratio, a significant increase in the percentage of controlled patients after treatment, and a significant reduction in urinary albumin excretion.
SUMMARY: Nocturnal hypertension increases one's risk of cardiovascular and cerebrovascular events, nephrosclerosis, and progression to end-stage kidney failure in renal patients. Normalization of the circadian blood-pressure pattern is considered an important clinical goal of pharmacotherapy because it may slow the advance of renal injury. Chronotherapy provides a means of individualizing treatment of hypertension according to the circadian blood-pressure profile of each patient, and constitutes a new option in optimizing blood-pressure control and reducing risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046904     DOI: 10.1097/01.mnh.0000174144.07174.74

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  13 in total

Review 1.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

2.  Moderately increased albuminuria unmasked hypertension.

Authors:  Salvador Pertusa; Carlos Ramos-Lopez; Martha Martinez-Navas; Ana Palacios-Marqués
Journal:  BMJ Case Rep       Date:  2014-10-30

3.  Chronotherapy: a smart approach for refractory hypertension.

Authors:  Salvador Pertusa; Domingo Orozco-Beltran
Journal:  BMJ Case Rep       Date:  2009-07-26

Review 4.  Translating around the clock: Multi-level regulation of post-transcriptional processes by the circadian clock.

Authors:  Amber A Parnell; Aliza K De Nobrega; Lisa C Lyons
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

Review 5.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

6.  Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU.

Authors:  Shona Brothwell; Mary Dutton; Charles Ferro; Stephanie Stringer; Paul Cockwell
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

7.  Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study.

Authors:  David A Rorie; Amy Rogers; Isla S Mackenzie; Ian Ford; David J Webb; Bryan Willams; Morris Brown; Neil Poulter; Evelyn Findlay; Wendy Saywood; Thomas M MacDonald
Journal:  BMJ Open       Date:  2016-02-09       Impact factor: 2.692

8.  Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures.

Authors:  Amy Rogers; Ian Morrison; David A Rorie; Isla S Mackenzie; Thomas M MacDonald
Journal:  BMJ Open       Date:  2018-06-07       Impact factor: 2.692

9.  An agent-based model of cellular dynamics and circadian variability in human endotoxemia.

Authors:  Tung T Nguyen; Steve E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 10.  Therapeutic strategies to slow chronic kidney disease progression.

Authors:  Elke Wühl; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2008-03-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.